BetterLife Pharma (BETRF) Interest Expenses (2010 - 2026)
BetterLife Pharma (BETRF) posted quarterly Interest Expenses of -$16953.7 for Q2 2026, up 48.9% year-over-year from -$11386.3 in Q2 2025, and up 17.91% quarter-over-quarter from -$20651.6 in Q3 2025.
BetterLife Pharma (BETRF) Interest Expenses (2010 - 2026) Analysis & Trends
BetterLife Pharma's Interest Expenses history runs 17 years deep, the most recent figure standing at -$16953.7 for Q2 2026.
- In Q2 2026, Interest Expenses rose 48.9% year-over-year to -$16953.7; the TTM figure through Apr 2026 stood at -$70779.8 (down 295.93% YoY), while the FY2026 annual figure was $111250.2, down 4.34% from the prior year.
- Interest Expenses for Q2 2026 stood at -$16953.7, up from -$20651.6 in the prior quarter.
- The five-year high for Interest Expenses was $134039.8 in Q1 2025, with the low at -$137687.3 in Q1 2023.
- The 5-year median for Interest Expenses is -$4786.8 (2023), against an average of -$5855.4.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses tumbled 2086.53% in 2024, then soared 1145.98% in 2025.
- BetterLife Pharma's Interest Expenses stood at -$1252.1 in 2022, then slumped by 313.26% to -$5174.3 in 2023, then sank by 497.02% to -$30891.6 in 2024, then jumped by 33.15% to -$20651.6 in 2025, then climbed by 17.91% to -$16953.7 in 2026.
- Business Quant data shows BETRF's Interest Expenses at -$16953.7 in Q2 2026, -$20651.6 in Q3 2025, and -$33174.4 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | BetterLife Pharma | 36.45 Mn | 36.42 Mn | - | -8,301.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -16,953.72 |
| Apr 30, 2026 | -16,953.72 |
| Jul 31, 2025 | -20,651.64 |
| Jul 31, 2025 | -20,651.64 |
| Apr 30, 2025 | -33,174.42 |
| Apr 30, 2025 | -33,174.42 |
| Jan 31, 2025 | 134,039.75 |
| Jan 31, 2025 | 134,039.75 |
| Oct 31, 2024 | -30,891.60 |
| Oct 31, 2024 | -30,891.60 |
| Jul 31, 2024 | -33,848.50 |
| Jul 31, 2024 | -33,848.50 |
| Apr 30, 2024 | -26,760.19 |
| Apr 30, 2024 | -26,760.19 |
| Jan 31, 2024 | 10,757.77 |
| Jan 31, 2024 | 10,757.77 |
| Oct 31, 2023 | -5,174.26 |
| Oct 31, 2023 | -5,174.26 |
| Jul 31, 2023 | -4,399.32 |
| Jul 31, 2023 | -4,399.32 |